KOPRANBSEKopran LtdMediumNeutral
Announced Mon, 18 May · 19:39 IST

Appointment of Director & Issue of shares in Subsidiary company Kopran Research laboratories ltd

Fund Raising View source PDF

KOPRAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.4%1-day move
₹164.00
prior close
₹165.75
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4+0.3+1.1+1.0+2.4+1.4+0.0+15.2+17.8+25.3+10.7+18.3+23.8
Up moveDown movePending
AI summary

Kopran's subsidiary Kopran Research Laboratories Ltd (KRLL) has announced two key decisions from its Board meeting on May 18, 2026. First, Mr. Chandresh Gandhi, currently an Independent Director of Kopran Ltd, has been appointed as Additional Director (Non-Executive, Independent Category) of KRLL for a 5-year term. Second, KRLL will issue Rights shares in the ratio of 1:12 (1 share for every 12 held) with face value of Rs. 10 and a premium of Rs. 90 per share, totaling an issue price of Rs. 100 per share. The company aims to raise Rs. 18.75 crore through this rights issue, which will be used for working capital requirements.

Likely market impact

The rights issue will provide KRLL with Rs. 18.75 crore for working capital, potentially strengthening the subsidiary's operations. Existing Kopran shareholders will receive rights entitlement in the ratio 1:12, offering them the opportunity to maintain their proportional ownership in KRLL at Rs. 100 per share.